Get the Stockscreener App
0.5751
2.70%
0.0151
Pre-market:
.57
-0.0051
-0.89%
Longeveron Inc stock is traded at $0.5751, with a volume of 47,063.
It is up +2.70% in the last 24 hours and up +8.31% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.56
Open:
$0.56
24h Volume:
47,063
Relative Volume:
0.16
Market Cap:
$12.27M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.086
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
+7.33%
1M Performance:
+8.31%
6M Performance:
-28.11%
1Y Performance:
-64.93%
1-Day Range:
$0.548
$0.58
1-Week Range:
$0.525
$0.58
52-Week Range:
$0.492
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5751 | 11.95M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Movement Recap: Can Longeveron Inc outperform in the next rally2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Q1 Earnings Forecast for Longeveron Issued By Zacks Research - Defense World
Will Longeveron Inc. stock hit new highs in YEARMarket Performance Recap & Intraday High Probability Alerts - mfd.ru
Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday - Defense World
Trade Recap: Does Longeveron Inc offer margin of safetyJuly 2025 Sentiment & Free High Return Stock Watch Alerts - baoquankhu1.vn
Is Longeveron Inc. a strong candidate for buy and holdQuarterly Risk Review & Consistent Profit Focused Trading Strategies - mfd.ru
Longeveron Appoints Stephen Willard as CEO - citybiz
Surprises Report: Is Longeveron Inc stock a value trapJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives - The Globe and Mail
Is Longeveron Inc. on track to beat earningsJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results - Investing.com Australia
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results By Investing.com - Investing.com South Africa
Longeveron Appoints New CEO to Drive Growth - Intellectia AI
Longeveron Inc. Appoints Stephen H. Willard as New CEO, Succeeding Than Powell - Quiver Quantitative
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - The Manila Times
New Longeveron CEO steps in as pivotal stem cell trial nears - Stock Titan
Gains Recap: Is Longeveron Inc. stock supported by strong fundamentalsEarnings Overview Report & Long-Term Investment Growth Plans - mfd.ru
Is Longeveron Inc. exposed to currency risksQuarterly Market Review & High Accuracy Trade Alerts - mfd.ru
How cyclical is Longeveron Incs revenue streamEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Is Longeveron Inc. still a buy after recent gains2025 Earnings Surprises & Consistent Return Investment Signals - mfd.ru
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - The Manila Times
Congress renews voucher that may speed Longeveron heart therapy for babies - Stock Titan
Merger Talk: Is WABC part of any major indexVolume Spike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Catalysts: Will Longeveron Inc benefit from rising consumer demand2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Longeveron receives Japanese patent for stem cell potency assay methods By Investing.com - Investing.com South Africa
Longeveron receives Japanese patent for stem cell potency assay methods - Investing.com
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
Longeveron prepares for pivotal HLHS therapy data with FDA meeting By Investing.com - Investing.com Nigeria
Gainers Report: Whats the outlook for CrowdStrike Holdings Incs sectorTake Profit & Growth Focused Stock Reports - baoquankhu1.vn
Published on: 2026-01-27 00:29:51 - baoquankhu1.vn
Longeveron Granted FDA Type C Meeting Ahead Of Pivotal ELPIS II Data For HLHS - Nasdaq
Longeveron prepares for pivotal HLHS therapy data with FDA meeting - Investing.com
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) - The Manila Times
Stem cell therapy for rare infant heart defect moves into key FDA talks - Stock Titan
Aug Big Picture: Is Longeveron Inc exposed to political riskJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
Revenue Check: What is Longeveron Incs revenue forecastQuarterly Trade Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Buyback Watch: What is the implied volatility of Telefnica Brasil SA Depositary ReceiptJuly 2025 Levels & Real-Time Price Movement Reports - baoquankhu1.vn
Portfolio Recap: Can Longeveron Inc continue delivering strong returnsQuarterly Portfolio Review & Comprehensive Market Scan Insights - baoquankhu1.vn
Surprises Report: Is Longeveron Inc stock a defensive play in 2025Quarterly Market Review & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Options Flow: Is Longeveron Inc stock a top momentum play2025 Technical Overview & Free Real-Time Market Sentiment Alerts - Bộ Nội Vụ
Can Longeveron Inc. stock attract ESG capital inflowsJuly 2025 Technicals & Consistent Profit Trade Alerts - Улправда
Is Longeveron Inc. stock positioned for long term growthEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Why Longeveron Inc. stock is considered a top pickJuly 2025 Volume & Consistent Return Strategy Ideas - ulpravda.ru
Will Longeveron Inc. stock continue upward momentumQuarterly Trade Review & Technical Pattern Alert System - Улправда
Is Longeveron Inc. stock a top momentum play2025 Market Overview & Long-Term Investment Growth Plans - Улправда
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Longeveron Inc.Class A Common stock (NQ: LGVN - FinancialContent
Longeveron Shares Jump as FDA Clears Phase 2 Trial for Pediatric Heart Therapy - MSN
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - marketscreener.com
Alzheimer’s ‘moonshot’ network taps Longeveron to join 2026 founder summit - Stock Titan
Longeveron (NASDAQ:LGVN) Stock Price Down 3.2% – What’s Next? - Defense World
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):